跳至主要内容
临床试验/NCT06276270
NCT06276270已完成不适用

Multi-centre, Open-label, First-in-man Study With Mucopad HA Used in Adult Patients Suffered From Oral Mucositis After Radiotherapy

Contipro Pharma a.s.5 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年12月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
50
试验地点
5
主要终点
Resolution of mucositis symptoms since completion of radiotherapy

研究概览

简要总结

The device´s intended use is to treat defects and/or lesions of the oral mucosa, e.g. oral mucositis.To prove safety of the device in terms of clinical results.

详细描述

This is an multi-centre, open-label, first-in-man prospective study.

Up to 60 patients in total will be involved in the open-label trial of new medical device - Mucopad HA. Eligible patients will be undergoing treatment with the device for up to 10 weeks, after which it is expected that there should be significant improvement in the healing process of oral mucositis after radiotherapy. It is considered as an improvement when there is a significant reduction or complete resolution of the mucositis. Mucositis will be assessed as a WHO scale.

Quality of life will be assessed by Oral Mucositis Daily Questionnaire (OMDQ) provided by FACIT. The FACIT and all related works are owned and copyrighted by, and the intellectual property of David Cella, Ph.D. Permission for use of the OMDQ questionnaire is obtained by contacting Dr. Cella at information@facit.org.

List of investigational sites is in appendix 7.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Sequential
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Oral Mucositis after radiotherapy of grade I - IV according to WHO
  • Patient willing and able to provide the written consent
  • Ability to communicate well with the investigator in the local language, and to understand and comply with the requirements of the study

排除标准

  • Age < 18 years
  • Pregnant or lactating women
  • Patients in terminal stage of living
  • Patients with known hypersensitivity or allergy to any of the substances contained in Medical Device
  • Alcohol or drug abuse

结局指标

主要结局

Resolution of mucositis symptoms since completion of radiotherapy

时间窗: 10 weeks

healing time

次要结局

  • Development of xerostomy(10 weeks)
  • - Pain management (VAS scale)(10 weeks)
  • Subjective evaluation on scale 1-5 of the treatment by investigator/ patient(10 weeks)

研究者

发起方
Contipro Pharma a.s.
申办方类型
Other
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验